Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,706 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.
Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS. Hu K, et al. Among authors: duan z. Phytomedicine. 2021 May;85:153242. doi: 10.1016/j.phymed.2020.153242. Epub 2020 May 16. Phytomedicine. 2021. PMID: 33867046 Free PMC article. Clinical Trial.
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.
Wei L, Xie Q, Hou JL, Jia J, Li W, Xu M, Li J, Wu S, Cheng J, Jiang J, Wang G, Yang Y, Mou Z, Gao ZL, Gong G, Niu JQ, Hu P, Tang H, Lin F, Dou X, Li L, Zhang LL, Nan Y, Massetto B, Yang JC, Knox SJ, Kersey K, German P, Mo H, Jiang D, Brainard DM, Jiang J, Ning Q, Duan Z. Wei L, et al. Among authors: duan z. J Gastroenterol Hepatol. 2018 Jun;33(6):1168-1176. doi: 10.1111/jgh.14102. Epub 2018 Mar 25. J Gastroenterol Hepatol. 2018. PMID: 29380415 Clinical Trial.
Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [Phytomedicine 85 (2021) 153242].
Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS. Hu K, et al. Among authors: duan z. Phytomedicine. 2021 Dec;93:153775. doi: 10.1016/j.phymed.2021.153775. Epub 2021 Oct 17. Phytomedicine. 2021. PMID: 34670161 No abstract available.
Efficacy and safety of Lianhua Qingwen capsules, a repurposed Chinese herb, in patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [Phytomedicine 85 (2021) 153242].
Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS. Hu K, et al. Among authors: duan z. Phytomedicine. 2022 Jan;94:153800. doi: 10.1016/j.phymed.2021.153800. Epub 2021 Oct 9. Phytomedicine. 2022. PMID: 34775361 Free PMC article. No abstract available.
Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
Wu T, Li J, Shao L, Xin J, Jiang L, Zhou Q, Shi D, Jiang J, Sun S, Jin L, Ye P, Yang L, Lu Y, Li T, Huang J, Xu X, Chen J, Hao S, Chen Y, Xin S, Gao Z, Duan Z, Han T, Wang Y, Gan J, Feng T, Pan C, Chen Y, Li H, Huang Y, Xie Q, Lin S, Li L, Li J; Chinese Group on the Study of Severe Hepatitis B (COSSH).. Wu T, et al. Among authors: duan z. Gut. 2018 Dec;67(12):2181-2191. doi: 10.1136/gutjnl-2017-314641. Epub 2017 Sep 19. Gut. 2018. PMID: 28928275
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.
Wei L, Xie Q, Hou JL, Tang H, Ning Q, Cheng J, Nan Y, Zhang L, Li J, Jiang J, McNabb B, Zhang F, Camus G, Mo H, Osinusi A, Brainard DM, Gong G, Mou Z, Wu S, Wang G, Hu P, Gao Y, Jia J, Duan Z. Wei L, et al. Among authors: duan z. Hepatol Int. 2018 Mar;12(2):126-132. doi: 10.1007/s12072-018-9856-z. Epub 2018 Apr 10. Hepatol Int. 2018. PMID: 29637511 Free PMC article. Clinical Trial.
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
Wei L, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-Sobol H, Mo H, Brainard DM, Yang YF, Dao L, Wang GQ, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J. Wei L, et al. Among authors: duan z. Lancet Gastroenterol Hepatol. 2019 Feb;4(2):127-134. doi: 10.1016/S2468-1253(18)30343-1. Epub 2018 Dec 14. Lancet Gastroenterol Hepatol. 2019. PMID: 30555048 Clinical Trial.
3,706 results